Trial reportBlood2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.Blood advances · 2020Trial
- Article
- Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.Nature communications · 2025Article
- Current approach to Waldenström macroglobulinemia.Blood reviews · 2023Review
- Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the "RTL" (regional Tuscan lymphoma network).Annals of hematology · 2023Article
- Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.Therapeutics and clinical risk management · 2022Review
- Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.Therapeutic advances in hematology · 2022Review
- How to Sequence Therapies in Waldenström Macroglobulinemia.Current treatment options in oncology · 2021Review
- Review
- Immunoglobulin M Paraproteinaemias.Cancers · 2020Review
- Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Review
- Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome.Journal of blood medicine · 2020Article
- Waldenström's macroglobulinemia front line treatment.HemaSphere · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.